Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension

被引:71
|
作者
Jiang, Baohua [1 ]
Deng, Yupu [1 ]
Suen, Colin [1 ,2 ]
Taha, Mohamad [1 ,2 ]
Chaudhary, Ketul R. [1 ]
Courtman, David W. [1 ]
Stewart, Duncan J. [1 ,2 ]
机构
[1] Ottawa Hosp Res Inst, Sinclair Ctr Regenerat Med, Ottawa, ON, Canada
[2] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada
基金
加拿大健康研究院;
关键词
pulmonary arterial hypertension; right ventricular remodeling; vascular remodeling; rodent strains; SU5416; BLOOD-INSTITUTE; PATHOLOGY; CELLS; PROLIFERATION; MECHANISMS; APOPTOSIS; SURVIVAL; CONFERS;
D O I
10.1165/rcmb.2014-0488OC
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We assessed the pulmonary hemodynamic response to vascular endothelial growth factor receptor, type 2, inhibition using SU5416 (SU) with and without chronic hypoxia (CH) in different background strains and colonies of rats. A single subcutaneous injection of SU (20 mg/kg) or vehicle was administered to different substrains of Sprague-Dawley (SD) rats, and they were compared with Lewis and Fischer rats, with and without exposure to CH (10% O-2 for 3 wk). Remarkably, a unique colony of SD rats from Charles River Laboratories, termed the SD-hyperresponsive type, exhibited severe pulmonary arterial hypertension (PAH) with SU alone, characterized by increased right ventricular systolic pressure, right ventricular/left ventricular plus septal weight ratio, and arteriolar occlusive lesions at 7-8 weeks (all P < 0.0001 versus vehicle). In contrast, the other SD substrain from Harlan Laboratories, termed SD-typical type, as well as Fischer rats, developed severe PAH only when exposed to SU and CH, whereas Lewis rats showed only a minimal response. All SD-typical type rats survived for up to 13 weeks after SU/CH, whereas SD-hyperresponsive type rats exhibited mortality after SU and SU/CH (35% and 50%, respectively) at 8 weeks. Fischer rats exposed to SU/CH exhibited the greatest mortality at 8 weeks (78%), beginning as early as 4 weeks after SU and preceded by right ventricle enlargement. Of note, a partial recovery of PAH after 8 weeks was observed in the SD-typical type substrain only. In conclusion, variation in strain, even between colonies of the same strain, has a remarkable influence on the nature and severity of the response to SU, consistent with an important role for genetic modifiers of the PAH phenotype.
引用
收藏
页码:461 / 468
页数:8
相关论文
共 50 条
  • [31] Aquaporin 1 confers apoptosis resistance in pulmonary arterial smooth muscle cells from the SU5416 hypoxia rat model
    Yun, Xin
    Niedermeyer, Shannon
    Andrade, Manuella Ribas
    Jiang, Haiyang
    Suresh, Karthik
    Kolb, Todd
    Damarla, Mahendra
    Shimoda, Larissa A.
    PHYSIOLOGICAL REPORTS, 2024, 12 (16):
  • [32] Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
    Liu, Ping
    Huang, Wen
    Ding, Yirui
    Wu, Jianbing
    Liang, Zhuangzhuang
    Huang, Zhangjian
    Xie, Weiping
    Kong, Hui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1653 - 1666
  • [33] Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension
    Yun, Xin
    Philip, Nicolas M.
    Jiang, Haiyang
    Smith, Zion
    Huetsch, John C.
    Damarla, Mahendra
    Suresh, Karthik
    Shimoda, Larissa A.
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [34] Cardiac Magnetic Resonance Imaging In The Su-5416/hypoxia/normoxia Rat Model Of Pulmonary Arterial Hypertension
    Mazer, A. J.
    Anderson, S. A.
    Gairhe, S.
    Holden, J.
    Solomon, M. A.
    Danner, R. L.
    Elinoff, J. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
    Alencar, Allan K. N.
    Pimentel-Coelho, Pedro M.
    Montes, Guilherme C.
    da Silva, Marina de M. C.
    Mendes, Luiza V. P.
    Montagnoli, Tadeu L.
    Silva, Ananssa M. S.
    Vasques, Juliana Ferreira
    Rosado-de-Castro, Paulo Henrique
    Gutfilen, Bianca
    Cunha, Valeria do M. N.
    Fraga, Aline G. M.
    Silva, Patricia M. R. E.
    Martins, Marco Aurelio
    Teixeira Ferreira, Tatiana Paula
    Mendes-Otero, Rosalia
    Trachez, Margarete M.
    Sudo, Roberto T.
    Zapata-Sudo, Gisele
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [36] Spontaneous Mutation in Pituitary Tumor Transforming Gene-1 Contributes to Increased Susceptibility to Severe Pulmonary Arterial Hypertension Induced by SU5416 in Rats
    Chaudhary, K. R.
    Deng, Y.
    Yang, A.
    Rowe, K.
    Cuppen, E.
    Stewart, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [37] Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling
    Chaudhary, Ketul R.
    Deng, Yupu
    Suen, Colin M.
    Taha, Mohamad
    Petersen, Thomas H.
    Mei, Shirley H. J.
    Stewart, Duncan J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (20) : 3976 - 3989
  • [38] Unilateral Pulmonary Artery Banding Prevents and Reverses Lung Micro-Vascular Loss in the Rat SU5416-Hypoxia Model of Severe Pulmonary Arterial Hypertension
    Deng, Yupu
    Chaudhary, Ketul R.
    Yang, Anli
    Rowe, Katelynn
    Stewart, Duncan J.
    CIRCULATION, 2019, 140
  • [39] Role of the Aryl Hydrocarbon Receptor in Su5416/Hypoxia-induced Pulmonary Hypertension: A New Mechanism for an "Old" Model
    Strielkov, Ievgen
    Weissmann, Norbert
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2018, 58 (03) : 279 - 281
  • [40] Riociguat can ameliorate bronchopulmonary dysplasia in the SU5416 induced rat experimental model
    Katsuragi, Shinichi
    Ishida, Hidekazu
    Suginobe, Hidehiro
    Tsuru, Hirofumi
    Wang, Renjie
    Yoshihara, Chika
    Ueyama, Atsuko
    Narita, Jun
    Ishii, Ryo
    Kogaki, Shigetoyo
    Ozono, Keiichi
    EXPERIMENTAL LUNG RESEARCH, 2021, 47 (08) : 382 - 389